{"id":23491,"date":"2022-12-20T21:56:00","date_gmt":"2022-12-20T13:56:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23491"},"modified":"2025-01-27T22:00:17","modified_gmt":"2025-01-27T14:00:17","slug":"pfizer-exercises-option-for-sisunatovir-rights-with-lianbio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23491","title":{"rendered":"Pfizer Exercises Option for Sisunatovir Rights with LianBio"},"content":{"rendered":"\n<p>US major Pfizer Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) has agreed with China-based LianBio (<a href=\"https:\/\/www.google.com\/finance\/quote\/LIANY:OTCMKTS\">OTCMKTS: LIANY<\/a>) to exercise an option to take development and commercialization rights to sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in the territories of mainland China, Hong Kong, Macau, and Singapore. The deal is signed under an earlier strategic collaboration between the two focused on expanding patient access to novel therapeutics in Greater China.<\/p>\n\n\n\n<p><strong>Deal Terms and Financials<\/strong><br>Under the terms of Pfizer\u2019s opt-in to the sisunatovir rights, LianBio will receive a USD 20 million upfront payment, to be released from previously restricted cash paid by Pfizer to LianBio in 2020 under their existing collaboration. Additionally, LianBio is eligible to receive up to USD 135 million in potential development and commercial milestone payments and tiered low single-digit royalties on sisunatovir net sales in the territories. Pfizer will assume all development and commercial activities and costs in the region, and will release LianBio from its royalty and milestone obligations for sisunatovir.<\/p>\n\n\n\n<p><strong>Drug Profile and Development<\/strong><br>Sisunatovir is an investigational orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell. It has been granted Fast Track designation status by the US FDA. In 2020, LianBio and Pfizer entered into a collaboration aimed at developing and commercializing transformative pharmaceutical products in Greater China leveraging both LianBio\u2019s and Pfizer\u2019s clinical development, regulatory and commercial expertise. Under the terms of the collaboration, Pfizer will contribute up to USD 70 million of non-dilutive capital toward in-licensing, development, and commercialization. At LianBio\u2019s discretion, products would be presented to Pfizer, and Pfizer allowed to take up development and commercial rights. The first program under development as part of that deal is sisunatovir. In June 2022, Pfizer acquired ReViral Ltd and its portfolio of RSV therapeutic candidates, with the exception of development and commercialization rights to sisunatovir in Mainland China, Hong Kong, Macau, and Singapore, which LianBio had previously in-licensed from ReViral in March 2021.<\/p>\n\n\n\n<p><strong>Clinical Progress and Future Prospects<\/strong><br>Sisunatovir was shown to significantly reduce viral load in a Phase II RSV human challenge study in healthy adults and is currently being evaluated in a global Phase II clinical study in children. This strategic move positions Pfizer and LianBio to further advance the development of sisunatovir, addressing significant unmet medical needs in RSV treatment and improving patient outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[995,863,68,309],"class_list":["post-23491","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-lianbio","tag-nyse-pfe","tag-pediatric-drugs","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Exercises Option for Sisunatovir Rights with LianBio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise an option to take development and commercialization rights to sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in the territories of mainland China, Hong Kong, Macau, and Singapore. The deal is signed under an earlier strategic collaboration between the two focused on expanding patient access to novel therapeutics in Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23491\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Exercises Option for Sisunatovir Rights with LianBio\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23491\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-20T13:56:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T14:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23491#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23491\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Exercises Option for Sisunatovir Rights with LianBio\",\"datePublished\":\"2022-12-20T13:56:00+00:00\",\"dateModified\":\"2025-01-27T14:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23491\"},\"wordCount\":398,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"LianBio\",\"NYSE: PFE\",\"Pediatric drugs\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23491#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23491\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23491\",\"name\":\"Pfizer Exercises Option for Sisunatovir Rights with LianBio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-20T13:56:00+00:00\",\"dateModified\":\"2025-01-27T14:00:17+00:00\",\"description\":\"US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise an option to take development and commercialization rights to sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in the territories of mainland China, Hong Kong, Macau, and Singapore. The deal is signed under an earlier strategic collaboration between the two focused on expanding patient access to novel therapeutics in Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23491#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23491\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23491#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Exercises Option for Sisunatovir Rights with LianBio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Exercises Option for Sisunatovir Rights with LianBio - Insight, China&#039;s Pharmaceutical Industry","description":"US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise an option to take development and commercialization rights to sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in the territories of mainland China, Hong Kong, Macau, and Singapore. The deal is signed under an earlier strategic collaboration between the two focused on expanding patient access to novel therapeutics in Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23491","og_locale":"en_US","og_type":"article","og_title":"Pfizer Exercises Option for Sisunatovir Rights with LianBio","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23491","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-20T13:56:00+00:00","article_modified_time":"2025-01-27T14:00:17+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23491#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23491"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Exercises Option for Sisunatovir Rights with LianBio","datePublished":"2022-12-20T13:56:00+00:00","dateModified":"2025-01-27T14:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23491"},"wordCount":398,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["LianBio","NYSE: PFE","Pediatric drugs","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23491#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23491","url":"https:\/\/flcube.com\/?p=23491","name":"Pfizer Exercises Option for Sisunatovir Rights with LianBio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-20T13:56:00+00:00","dateModified":"2025-01-27T14:00:17+00:00","description":"US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise an option to take development and commercialization rights to sisunatovir, a respiratory syncytial virus (RSV) therapeutic candidate, in the territories of mainland China, Hong Kong, Macau, and Singapore. The deal is signed under an earlier strategic collaboration between the two focused on expanding patient access to novel therapeutics in Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23491#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23491"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23491#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Exercises Option for Sisunatovir Rights with LianBio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23491"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23491\/revisions"}],"predecessor-version":[{"id":23492,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23491\/revisions\/23492"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}